Literature DB >> 33653904

Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.

Jeffrey Lambe1, Kathryn C Fitzgerald1, Olwen C Murphy1, Angeliki G Filippatou1, Elias S Sotirchos1, Grigorios Kalaitzidis1, Elena Vasileiou1, Nicole Pellegrini1, Esther Ogbuokiri1, Brandon Toliver1, Nicholas J Luciano1, Simidele Davis1, Nicholas Fioravante1, Ohemaa Kwakyi1, Hunter Risher1, Ciprian M Crainiceanu1, Jerry L Prince1, Scott D Newsome1, Ellen M Mowry1, Shiv Saidha1, Peter A Calabresi2.   

Abstract

OBJECTIVE: To evaluate whether a retinal spectral-domain optical coherence tomography (SD-OCT) assessment at baseline is associated with long-term disability worsening in people with multiple sclerosis (PwMS), we performed SD-OCT and Expanded Disability Status Scale (EDSS) assessments among 132 PwMS at baseline and at a median of 10 years later.
METHODS: In this prospective, longitudinal study, participants underwent SD-OCT, EDSS, and visual acuity (VA) assessments at baseline and at follow-up. Statistical analyses were performed using generalized linear regression models, adjusted for age, sex, race, multiple sclerosis (MS) subtype, and baseline disability. We defined clinically meaningful EDSS worsening as an increase of ≥2.0 if baseline EDSS score was <6.0 or an increase of ≥1.0 if baseline EDSS score was ≥6.0.
RESULTS: A total of 132 PwMS (mean age 43 years; 106 patients with relapsing-remitting MS) were included in analyses. Median duration of follow-up was 10.4 years. In multivariable models excluding eyes with prior optic neuritis, relative to patients with an average baseline ganglion cell + inner plexiform layer (GCIPL) thickness ≥70 µm (the mean GCIPL thickness of all eyes at baseline), an average baseline GCIPL thickness <70 µm was associated with a 4-fold increased odds of meaningful EDSS worsening (adjusted odds ratio [OR] 3.97, 95% confidence interval [CI] 1.24-12.70; p = 0.02) and an almost 3-fold increased odds of low-contrast VA worsening (adjusted OR 2.93, 95% CI 1.40-6.13; p = 0.04).
CONCLUSIONS: Lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS. Accordingly, SD-OCT at a single time point may help guide therapeutic decision-making among individual PwMS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower baseline GCIPL thickness on SD-OCT is independently associated with long-term disability worsening in MS.
© 2021 American Academy of Neurology.

Entities:  

Mesh:

Year:  2021        PMID: 33653904      PMCID: PMC8166450          DOI: 10.1212/WNL.0000000000011788

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.

Authors:  L J Balcer; M L Baier; V S Pelak; R J Fox; S Shuwairi; S L Galetta; G R Cutter; M G Maguire
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

Review 2.  Current and emerging treatment of multiple sclerosis.

Authors:  Felecia M Hart; Jacquelyn Bainbridge
Journal:  Am J Manag Care       Date:  2016-06       Impact factor: 2.229

Review 3.  Evolving management of optic neuritis and multiple sclerosis.

Authors:  Anthony C Arnold
Journal:  Am J Ophthalmol       Date:  2005-06       Impact factor: 5.258

Review 4.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

Review 5.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

6.  Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.

Authors:  S Schippling; L J Balk; F Costello; P Albrecht; L Balcer; P A Calabresi; J L Frederiksen; E Frohman; A J Green; A Klistorner; O Outteryck; F Paul; G T Plant; G Traber; P Vermersch; P Villoslada; S Wolf; A Petzold
Journal:  Mult Scler       Date:  2014-06-16       Impact factor: 6.312

Review 7.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

8.  The OSCAR-IB consensus criteria for retinal OCT quality assessment.

Authors:  Prejaas Tewarie; Lisanne Balk; Fiona Costello; Ari Green; Roland Martin; Sven Schippling; Axel Petzold
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

9.  Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis.

Authors:  Julio J González-López; Gema Rebolleda; Marina Leal; Noelia Oblanca; Francisco J Muñoz-Negrete; Lucienne Costa-Frossard; José C Alvarez-Cermeño
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

Review 10.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

View more
  7 in total

1.  Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.

Authors:  Elisabeth Olbert; Walter Struhal
Journal:  Wien Med Wochenschr       Date:  2022-03-28

2.  Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.

Authors:  Christian Cordano; Bardia Nourbakhsh; Hao H Yiu; Nico Papinutto; Eduardo Caverzasi; Ahmed Abdelhak; Frederike C Oertel; Alexandra Beaudry-Richard; Adam Santaniello; Simone Sacco; Daniel J Bennett; Apraham Gomez; Christina J Sigurdson; Stephen L Hauser; Roberta Magliozzi; Bruce A C Cree; Roland G Henry; Ari J Green
Journal:  Neurology       Date:  2022-08-29       Impact factor: 11.800

3.  CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography.

Authors:  Jens Ingwersen; Jonas Graf; Julia Kluge; Margit Weise; Michael Dietrich; John-Ih Lee; Jens Harmel; Hans-Peter Hartung; Tobias Ruck; Sven G Meuth; Philipp Albrecht; Orhan Aktas; Marius Ringelstein
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-10-19

4.  Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity.

Authors:  Joke Temmerman; Floris Van Der Veken; Sebastiaan Engelborghs; Kaat Guldolf; Guy Nagels; Dirk Smeets; Gert-Jan Allemeersch; Lars Costers; Marie B D'hooghe; Anne-Marie Vanbinst; Jeroen Van Schependom; Maria Bjerke; Miguel D'haeseleer
Journal:  J Clin Med       Date:  2022-01-20       Impact factor: 4.241

5.  Pathways to cures for multiple sclerosis: A research roadmap.

Authors:  Bruce F Bebo; Mark Allegretta; Douglas Landsman; Kathy M Zackowski; Fiona Brabazon; Walter A Kostich; Timothy Coetzee; Alexander Victor Ng; Ruth Ann Marrie; Kelly R Monk; Amit Bar-Or; Caroline C Whitacre
Journal:  Mult Scler       Date:  2022-03       Impact factor: 6.312

6.  Comparison of Machine Learning Methods Using Spectralis OCT for Diagnosis and Disability Progression Prognosis in Multiple Sclerosis.

Authors:  Alberto Montolío; José Cegoñino; Elena Garcia-Martin; Amaya Pérez Del Palomar
Journal:  Ann Biomed Eng       Date:  2022-02-26       Impact factor: 3.934

Review 7.  Optical Coherence Tomography and Optical Coherence Tomography with Angiography in Multiple Sclerosis.

Authors:  Ioannis-Nikolaos Chalkias; Christos Bakirtzis; Demetrios Pirounides; Marina Kleopatra Boziki; Nikolaos Grigoriadis
Journal:  Healthcare (Basel)       Date:  2022-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.